{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:50Z","timestamp":1792785050612,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japan Society for the Promotion of Science","award":["Grant-in-Aid for JSPS Research Fellows"],"award-info":[{"award-number":["Grant-in-Aid for JSPS Research Fellows"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Japan Society for the Promotion of Science","award":["21K16822"],"award-info":[{"award-number":["21K16822"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Japan Society for the Promotion of Science","award":["19K18651"],"award-info":[{"award-number":["19K18651"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-59944-3","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:05:35Z","timestamp":1782767135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elimusertib exhibits strong synergy with olaparib in ovarian cancer organoids through replication fork interference"],"prefix":"10.1038","volume":"16","author":[{"given":"Mio","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Ookubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Toyonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Saotome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yoshihama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyo","family":"Jisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Dozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8214-2242","authenticated-orcid":false,"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"59944_CR1","doi-asserted-by":"publisher","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249, https:\/\/doi.org\/10.3322\/caac.21660 (2021).","DOI":"10.3322\/caac.21660"},{"key":"59944_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","volume":"151","author":"LC Peres","year":"2018","unstructured":"Peres, L. C. et al. Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol. Oncol. 151, 53\u201360. https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.016 (2018).","journal-title":"Gynecol. Oncol."},{"key":"59944_CR3","unstructured":"Patient Annual Report for 2021, Japan Society of Obstetrics and Gyneoclogy."},{"key":"59944_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.Cd-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D\u2019Andrea, A. D. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian Cancer. Cancer Discov. 5, 1137\u20131154. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0714 (2015).","journal-title":"Cancer Discov."},{"key":"59944_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917. https:\/\/doi.org\/10.1038\/nature03443 (2005).","journal-title":"Nature"},{"key":"59944_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921. https:\/\/doi.org\/10.1038\/nature03445 (2005).","journal-title":"Nature"},{"key":"59944_CR7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/s1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721\u20131731. https:\/\/doi.org\/10.1016\/s1470-2045(21)00531-3 (2021).","journal-title":"Lancet Oncol."},{"key":"59944_CR8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1007\/s10147-022-02212-x","volume":"27","author":"T Yoshihama","year":"2022","unstructured":"Yoshihama, T. et al. Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer. Int. J. Clin. Oncol. 27, 1644\u20131650. https:\/\/doi.org\/10.1007\/s10147-022-02212-x (2022).","journal-title":"Int. J. Clin. Oncol."},{"key":"59944_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361 (2019).","journal-title":"N. Engl. J. Med."},{"key":"59944_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.15252\/msb.20177697","volume":"13","author":"J Jabs","year":"2017","unstructured":"Jabs, J. et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol. Syst. Biol. 13, 955. https:\/\/doi.org\/10.15252\/msb.20177697 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"59944_CR11","doi-asserted-by":"publisher","unstructured":"\u00c5kerlund, E. et al. The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients. npj Precis. Oncol. 7, 111, https:\/\/doi.org\/10.1038\/s41698-023-00463-z (2023).","DOI":"10.1038\/s41698-023-00463-z"},{"key":"59944_CR12","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.1038\/s41598-020-69488-9","volume":"10","author":"Y Nanki","year":"2020","unstructured":"Nanki, Y. et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci. Rep. 10, 12581. https:\/\/doi.org\/10.1038\/s41598-020-69488-9 (2020).","journal-title":"Sci. Rep."},{"key":"59944_CR13","doi-asserted-by":"publisher","unstructured":"Zeng, M. et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12\/13. eLife 7, https:\/\/doi.org\/10.7554\/eLife.39030 (2018).","DOI":"10.7554\/eLife.39030"},{"key":"59944_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1535-7163.Mct-19-0052","volume":"19","author":"HA Kenny","year":"2020","unstructured":"Kenny, H. A. et al. Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis. Mol. Cancer Ther. 19, 52\u201362. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-0052 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"59944_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","volume":"2","author":"N Phan","year":"2019","unstructured":"Phan, N. et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2, 78. https:\/\/doi.org\/10.1038\/s42003-019-0305-x (2019).","journal-title":"Commun. Biol."},{"key":"59944_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2767-9764.Crc-25-0024","volume":"5","author":"T Yoshimura","year":"2025","unstructured":"Yoshimura, T. et al. High-throughput drug screening of clear cell ovarian cancer organoids reveals vulnerability to proteasome inhibitors and dinaciclib and identifies AGR2 as a therapeutic target. Cancer Res. Commun. 5, 1018\u20131033. https:\/\/doi.org\/10.1158\/2767-9764.Crc-25-0024 (2025).","journal-title":"Cancer Res. Commun."},{"key":"59944_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1535-7163.Mct-23-0094","volume":"23","author":"FF Pusch","year":"2024","unstructured":"Pusch, F. F. et al. Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models. Mol. Cancer Ther. 23, 507\u2013519. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0094 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"59944_CR18","doi-asserted-by":"publisher","unstructured":"Ahmed, S. et al. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomed. Pharmacother. Biomed. Pharmacother. 155, 113797, https:\/\/doi.org\/10.1016\/j.biopha.2022.113797 (2022).","DOI":"10.1016\/j.biopha.2022.113797"},{"key":"59944_CR19","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/s0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 390, 1949\u20131961. https:\/\/doi.org\/10.1016\/s0140-6736(17)32440-6 (2017).","journal-title":"Lancet (London, England)"},{"key":"59944_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3 (2020).","journal-title":"Nature"},{"key":"59944_CR21","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2 (2020).","journal-title":"Nat. Commun."},{"key":"59944_CR22","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858 (2018).","journal-title":"N. Engl. J. Med."},{"key":"59944_CR23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962 (2019).","journal-title":"N. Engl. J. Med."},{"key":"59944_CR24","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126. https:\/\/doi.org\/10.1038\/ncomms3126 (2013).","journal-title":"Nat. Commun."},{"key":"59944_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ygyno.2015.05.040","volume":"138","author":"AK Mitra","year":"2015","unstructured":"Mitra, A. K. et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol. Oncol. 138, 372\u2013377. https:\/\/doi.org\/10.1016\/j.ygyno.2015.05.040 (2015).","journal-title":"Gynecol. Oncol."},{"key":"59944_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071939","author":"A Bradbury","year":"2020","unstructured":"Bradbury, A., O\u2019Donnell, R., Drew, Y., Curtin, N. J. & Sharma Saha, S. Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting. Cancers https:\/\/doi.org\/10.3390\/cancers12071939 (2020).","journal-title":"Cancers"},{"key":"59944_CR27","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.Ccr-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 3097\u20133108. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2273 (2017).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"59944_CR28","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.214080.113","volume":"27","author":"FB Couch","year":"2013","unstructured":"Couch, F. B. et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 27, 1610\u20131623. https:\/\/doi.org\/10.1101\/gad.214080.113 (2013).","journal-title":"Genes Dev."},{"key":"59944_CR29","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: Ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18, 622\u2013636. https:\/\/doi.org\/10.1038\/nrm.2017.67 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"59944_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza, A. et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature 559, 279\u2013284. https:\/\/doi.org\/10.1038\/s41586-018-0261-5 (2018).","journal-title":"Nature"},{"key":"59944_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature25507","volume":"555","author":"M Macheret","year":"2018","unstructured":"Macheret, M. & Halazonetis, T. D. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature 555, 112\u2013116. https:\/\/doi.org\/10.1038\/nature25507 (2018).","journal-title":"Nature"},{"key":"59944_CR32","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1158\/1078-0432.Ccr-21-1643","volume":"28","author":"Z Cheng","year":"2022","unstructured":"Cheng, Z. et al. The genomic landscape of early-stage ovarian high-grade serous carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 28, 2911\u20132922. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1643 (2022).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"59944_CR33","doi-asserted-by":"publisher","unstructured":"Cheng, Z. et al. The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions. 2024.2003.2011.584384, https:\/\/doi.org\/10.1101\/2024.03.11.584384 %J bioRxiv (2024).","DOI":"10.1101\/2024.03.11.584384"},{"key":"59944_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","volume":"20","author":"R Drost","year":"2011","unstructured":"Drost, R. et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20, 797\u2013809. https:\/\/doi.org\/10.1016\/j.ccr.2011.11.014 (2011).","journal-title":"Cancer Cell"},{"key":"59944_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord, C. J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287\u2013294. https:\/\/doi.org\/10.1038\/nature10760 (2012).","journal-title":"Nature"},{"key":"59944_CR36","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","volume":"118","author":"P Neri","year":"2011","unstructured":"Neri, P. et al. Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors. Blood 118, 6368\u20136379. https:\/\/doi.org\/10.1182\/blood-2011-06-363911 (2011).","journal-title":"Blood"},{"key":"59944_CR37","doi-asserted-by":"publisher","unstructured":"Alagpulinsa, D. A., Ayyadevara, S., Yaccoby, S. & Shmookler Reis, R. J. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Molecular cancer therapeutics 15, 241\u2013250, https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0660 (2016).","DOI":"10.1158\/1535-7163.Mct-15-0660"},{"key":"59944_CR38","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson, S. F. et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 17, 2367\u20132381. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.077 (2016).","journal-title":"Cell Rep."},{"key":"59944_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah, P. D. et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol. Oncol. 163, 246\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024 (2021).","journal-title":"Gynecol. Oncol."},{"key":"59944_CR40","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.Ccr-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in Acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 29, 2800\u20132807. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2444 (2023).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"59944_CR41","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-23-0402","author":"U Jo","year":"2024","unstructured":"Jo, U. et al. The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs. Mol. Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0402 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"59944_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.Mct-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner, A. M. et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol. Cancer Ther. 19, 26\u201338. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-0019 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"59944_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100017","volume":"2","author":"FM Barnieh","year":"2021","unstructured":"Barnieh, F. M., Loadman, P. M. & Falconer, R. A. Progress towards a clinically-successful ATR inhibitor for cancer therapy. Current Res. Pharmacol. Drug Discov. 2, 100017. https:\/\/doi.org\/10.1016\/j.crphar.2021.100017 (2021).","journal-title":"Current Res. Pharmacol. Drug Discov."},{"key":"59944_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.Cd-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0868 (2021).","journal-title":"Cancer Discov."},{"key":"59944_CR45","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote, K. M. et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J. Med. Chem. 61, 9889\u20139907. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01187 (2018).","journal-title":"J. Med. Chem."},{"key":"59944_CR46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40262-018-0714-x","volume":"58","author":"D Zhou","year":"2019","unstructured":"Zhou, D. et al. Bridging olaparib capsule and tablet formulations using population pharmacokinetic meta-analysis in oncology patients. Clin. Pharmacokinet. 58, 615\u2013625. https:\/\/doi.org\/10.1007\/s40262-018-0714-x (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"59944_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol. Rev."},{"key":"59944_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s44276-025-00145-2","volume":"3","author":"T Yoshimura","year":"2025","unstructured":"Yoshimura, T. et al. Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification. BJC Rep 3, 37. https:\/\/doi.org\/10.1038\/s44276-025-00145-2 (2025).","journal-title":"BJC Rep"},{"key":"59944_CR49","doi-asserted-by":"publisher","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS biology 18, e3000410, https:\/\/doi.org\/10.1371\/journal.pbio.3000410 (2020).","DOI":"10.1371\/journal.pbio.3000410"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59944-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:41:32Z","timestamp":1790548892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59944-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59944"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59944-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Aki Ookubo and Manabu Itoh are employees of JSR Corporation. Tatsuyuki Chiyoda reports receiving a research grant from JSR Corporation and Takeda Pharmaceuticals Company Limited. The other authors declare no conflict of interest regarding this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was collected from all patients (approval No. 20070081). All procedures involving mice were conducted in accordance with protocols approved by the Keio University School of Medicine. This study adhered to the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29939"}}